Search hospitals > Ohio > Barberton

Summa Health System - Barberton Campus

Claim this profile
Barberton, Ohio 44203
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Prostate Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
121 reported clinical trials
2 medical researchers
Photo of Summa Health System - Barberton Campus in BarbertonPhoto of Summa Health System - Barberton Campus in Barberton

Summary

Summa Health System - Barberton Campus is a medical facility located in Barberton, Ohio. This center is recognized for care of Breast Cancer, Cancer, Prostate Cancer, Lung Cancer, Adenocarcinoma and other specialties. Summa Health System - Barberton Campus is involved with conducting 121 clinical trials across 174 conditions. There are 2 research doctors associated with this hospital, such as Bradley T. Clifford and Desiree E. Doncals.

Area of expertise

1Breast Cancer
Global Leader
Summa Health System - Barberton Campus has run 30 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
PR positive
2Cancer
Global Leader
Summa Health System - Barberton Campus has run 26 trials for Cancer. Some of their research focus areas include:
Stage III
p16 positive
p16 negative

Top PIs

Clinical Trials running at Summa Health System - Barberton Campus

Breast Cancer
Prostate Cancer
Oropharyngeal Carcinoma
Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Recurrence
Oropharyngeal Cancer
Cancer
Laryngeal Squamous Cell Carcinoma
Prostate Adenocarcinoma
Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Summa Health System - Barberton Campus?
Summa Health System - Barberton Campus is a medical facility located in Barberton, Ohio. This center is recognized for care of Breast Cancer, Cancer, Prostate Cancer, Lung Cancer, Adenocarcinoma and other specialties. Summa Health System - Barberton Campus is involved with conducting 121 clinical trials across 174 conditions. There are 2 research doctors associated with this hospital, such as Bradley T. Clifford and Desiree E. Doncals.